American Diabetes Association
Supplementary_material_drug_x_paper_DC_paper_Submitted_R1.pdf (443.48 kB)

The initiation of new glucose lowering therapies may act to reduce physical activity levels: pooled analysis from three randomised trials

Download (443.48 kB)
posted on 2022-08-19, 14:40 authored by Thomas Yates, Jack A Sargeant, James A King, Joe Henson, Charlotte L Edwardson, Emma Redman, Gaurav S, Gulsin, Emer M Brady, Ehtasham Ahmad, David J Stensel, David R Webb, Gerry P McCann, Kamlesh Khunti, Melanie J Davies


OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown.

RESEARCH DESIGN AND METHODS. We pooled data (n = 148) from three randomised trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison to sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies on accelerometer-assessed physical activity.

RESULTS: Liraglutide (-1144 steps/day; 95% CI -2069, -220), empagliflozin (-1132 steps/day; -1739, -524) and sitagliptin (-852 steps/day; -1625, -78) resulted in reduced total daily physical activity after 6 months (p< 0.01 vs. control). Moderate-to-vigorous intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity.

CONCLUSIONS: The initiation of all glucose lowering therapies was associated with reduced physical activity, warranting further investigation. 


The SEESAW trial was funded by an investigator-initiated grant from Boehringer-Ingelheim. The LYDIA trial was funded by an investigator-initiated grant from Novo Nordisk. The DIASTOLIC trial was funded by a grant from the National Institute for Health Research (CDF 2014-07-045). The funders had no role in collection, analysis or interpretation of data, nor writing of this manuscript. This study was also supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.


Usage metrics

    Diabetes Care


    Ref. manager